Technology Advantages

Technology Advantages

Our Vaccine Platform Advantages:

  • Rapid and Flexible Cell Culture Manufacturing Systems.
  • Platform technology suitable for developing and producing multiple distinct vaccines.
  • Eliminates the need for eggs or live/attenuated viruses during production.
  • Highly immunogenic vaccines eliciting robust immune responses.
  • Safe product without the need for inactivation as it uses non-infectious, non-pathogenic organisms for humans.
  • Reduced safety concerns during production requiring no containment facilities.
  • High yield, larger production capabilities, shorter production time and lower cost.
  • Reduced Manufacturing Costs & Capital requirements
  • Creation of Master Cell Banks (Continuous Cell Line System).
  • Rapid Response to emerging pandemic or epidemic influenza virus strains due to fast and flexible system.

TechnoVax Specific Advantages:

  • TechnoVax has developed the Next generation VLP technology platform.
  • Pathway has been cleared for VLP-based vaccines (ph. I/II) by others biotech companies using first generation VLP technology, thus risk of failure is limited.
  • Universal flu candidate will completely disrupt the current worldwide flu market and its commercialization.
  • Pulmonary inhaled technology coupled with our vaccine platform will be a game changer in many aspects of the vaccine field (“no cold” storage, streamlined distribution and self-administration).
  • Our technology is a powerful research system for vaccine prototyping or candidate identification.